In terms of influence on treatment, a retrospective analysis of the RATIFY trial—a phase 3 trial that demonstrated the efficacy of adding midostaurin to standard chemotherapy in patients with FLT3-mutated AML—indicated that the first-generation FLT3 inhibitor was equally effective for all ELN risk groups regardless of NPM1 mutation status [81]. The gene discussed is NPM1; the disease is acute myeloid leukemia.